Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 0.2% – What’s Next?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI)’s stock price was down 0.2% during trading on Friday . The company traded as low as $8.90 and last traded at $8.90. Approximately 33,040 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 46,134 shares. The stock had previously closed at $8.92.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their target price on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, April 21st.

Greenwich LifeSciences Trading Down 0.2%

The company’s 50 day moving average price is $9.59 and its two-hundred day moving average price is $11.12. The firm has a market cap of $118.99 million, a PE ratio of -7.06 and a beta of 1.69.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Tuesday, May 20th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Equities research analysts expect that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Insider Activity at Greenwich LifeSciences

In related news, CEO Snehal Patel purchased 3,600 shares of the firm’s stock in a transaction on Friday, April 25th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $35,568.00. Following the purchase, the chief executive officer now directly owns 5,570,602 shares in the company, valued at $55,037,547.76. This trade represents a 0.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have bought 18,100 shares of company stock worth $164,835. 51.67% of the stock is owned by corporate insiders.

Institutional Trading of Greenwich LifeSciences

Several hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its stake in Greenwich LifeSciences by 54.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock worth $32,000 after purchasing an additional 1,008 shares in the last quarter. Barclays PLC lifted its stake in Greenwich LifeSciences by 12.7% in the 4th quarter. Barclays PLC now owns 9,648 shares of the company’s stock worth $108,000 after purchasing an additional 1,088 shares in the last quarter. GAMMA Investing LLC purchased a new stake in Greenwich LifeSciences in the 1st quarter worth $126,000. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Greenwich LifeSciences by 15.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company’s stock worth $181,000 after buying an additional 2,552 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.